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3′ end RNA sequencingLeiomyosarcoma (LMS) is a malignant neoplasm with smooth muscle differentiation. Little is known about its
molecular heterogeneity and no targeted therapy currently exists for LMS. We performed expression proﬁling
on 99 cases of LMSwith 3′ end RNA sequencing (3SEQ) and demonstrated the existence of 3 molecular subtypes
in this cohort. We consequently showed that these molecular subtypes are reproducible using an independent
cohort of 82 LMS cases from TCGA. Two new formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue-compatible diag-
nostic immunohistochemical markers were identiﬁed for two of the three subtypes: LMOD1 for subtype I LMS
and ARL4C for subtype II LMS. Subtype I LMS and subtype II LMS were associated with good and poor prognosis,
respectively. Here, we describe the details of LMS diagnosis, RNA isolation, 3SEQ library construction, 3SEQ se-
quencing data analysis and molecular subtype determination. The 3SEQ data produced in this study was depos-
ited into Gene Expression Omnibus (GEO) under GSE45510.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Speciﬁcationsrganism/cell
line/tissueLeiomyosarcoma, FFPE tissues, humanx Male or female
quencer or array
type3′ end RNA sequencingata format TPM (transcripts per million reads) normalized matrix
xperimental
factorsArchival FFPE blocks for 99 cases of leiomyosarcomaxperimental
featuresTotal RNA isolation, oligo(dT) selection and gene expression
proﬁling of 99 leiomyosarcomasonsent IRB approval and a waiver of consent due to the archival
nature of the specimensmple source
locationNine hospitals from United States, Canada and Europe
(see Experimental design)1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45510., Stanford University School of
. This is an open access article under2. Experimental design, materials and methods
2.1. Experimental design
To explore themolecular subtypes of leiomyosarcoma (LMS), paraf-
ﬁn blocks of 99 LMS cases from 1991 to 2012 from nine hospitals
(Stanford Hospital, Brigham andWomen's Hospital, McKay-Dee Hospi-
tal Center, St. Luke's Hospital, Baptist Health Medical Center, Ingalls
Hospital, Vancouver General Hospital, Hospital de la Santa Creu i Sant
Pau and Alta Bates SummitMedical Center), were collectedwith IRB ap-
proval and a waiver of consent due to the archival nature of the speci-
mens. The total RNA was extracted for these cases and subsequently
analyzed by 3′ end RNA sequencing. Consensus Clustering was used to
determine the optimal number of subtypes and Silhouette analysis
was then performed to measure the conﬁdence of subtype assignment
per case. To test the reproducibility of molecular subtype classiﬁcation
from the 3SEQ dataset, the expression proﬁles (RNASeq data) of 82 ad-
ditional LMS cases were downloaded from The Cancer Genome Atlas
(TCGA) database and analyzed in an identical way to the 3SEQ data.
Subclass mapping was then used to ﬁnd the common subtypes identi-
ﬁed in both datasets [1].2.2. Materials
The LMS cases used in this study were formalin-ﬁxed, parafﬁn-
embedded (FFPE) tissues.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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After LMS FFPE blocks were obtained, two experienced pathologists
(one from Stanford University and one from Brigham and Women's
Hospital) assessed and circled the regions comprised of LMS tumor
cells. Samples with paucity of material or poor preservation of material
were excluded. Multiple 2 mm-diameter cores from the areas circled
were re-embedded longitudinally into new parafﬁn blocks, and were
sectioned and re-evaluated for the second time by H&E staining to en-
sure the purity of the samples. Only cores with ≥90% of tumor cells
were processed for subsequent RNA extraction.
The total RNA of the LMS cases was extracted using RecoverAll™
Total Nucleic Acid Isolation kit (Ambion, Cat # 1975). The quality of
total RNA was assessed by agarose gel electrophoresis and used to de-
termine the amount of time necessary for shearing of the total RNA by
heat in ﬁrst strand buffer (Invitrogen, Cat # 18080-044) for subsequent
3SEQ library construction. The 3SEQ library construction included the
following steps; ﬁrst strand cDNA synthesis with Superscript III Reverse
Transcriptase (Invitrogen, Cat # 18080-044), second strand cDNA syn-
thesis with E coli DNA ligase (Invitrogen, Cat # 18052-019) and E. coli
DNA polymerase I (New England Biolab, Cat # M0209L), followed by
the addition of ‘A’ to the 3′ end of double strand DNA fragments with
Klenow exo (3′ to 5′ exominus, New England Biolab, Cat #M0212L), li-
gation of adapters (Illumina, Cat # 1001782—OLIGOMIX) with DNA li-
gase (New England Biolab, Cat # M2200L) and PCR ampliﬁcation using
2× Phusion PCR master mix (New England Biolab, Cat # F-531S) [1–6].
The detailed protocol of 3SEQ library construction can be accessed using
the following link, http://med.stanford.edu/labs/vanderijn-west/
documents/3endRNAseqlibraryconstruction_update_11_4_2014.doc.
The 3SEQ libraries were sent to the Stanford Center for Genomics
and Personalized Medicine to be sequenced directionally (36 bp) from
5′ end of mRNA fragments towards their poly(A) ends using Illumina
GA IIx and HiSeq 2000 machines (Illumina, Inc., San Diego, CA, USA).
The gene expression proﬁling data (3SEQ) have been deposited in the
Gene Expression Omnibus (GEO) and are publicly accessible through
GSE45510.
2.4. 3SEQ data analysis
Sequence reads (fastq format), ﬁrst ﬁltered for read quality, were re-
ﬁltered by fastx (fastx_artifacts_ﬁlter-v-Q 33, http://hannonlab.cshl.
edu/fastx_toolkit/index.html), and mapped to the transcriptome
(refMrna, downloaded from the UCSC genome browser, http://www.
genome.ucsc.edu/) using SOAP2, allowing at most two mismatches
[7]. The total numbers of sequence reads for each gene symbol from
the transcriptome mapping were determined and used to create the
gene-expression proﬁle matrix (22,144 genes). Read counts from each
library were normalized to transcripts per million reads (TPM). A cus-
tom Perl script was used to run the 3SEQ data processing and is publicly
available [3].
2.5. Subtype determinant and validation
To determine the optimal number of molecular subtypes of
leiomyosarcoma [1], the expression matrix of genes with the most var-
iant expression levels, ﬁltered with a standard deviation greater than
100 across all 99 LMS cases (1300 genes), were transformed by log2and gene-based centering [8]. Consensus Clustering (R package
ConsensusClusteringPlus) [9] was performed. This analysis was run
over 1000 iterations with the settings of “Distance− (1− Pearson cor-
relation), 80% sample resampling, 80% gene resampling, maximum
evaluated k of 12, and agglomerative hierarchical clustering algorithm”.
Based on the analysis we chose the optimal number of subtypes as
three. Expression proﬁling data of the 82 additional LMS cases by
RNASeq was downloaded from the TCGA database. To compare with
3SEQ data, the TCGA data were normalized into TPM and analyzed
with ConsensusClusteringPlus, as was done for the 3SEQ data.
To measure the reproducibility of the LMS subtypes, the cases from
both datasets (3SEQ and TCGA RNASeq)were evaluated using Silhouette
analysis [10], where an LMS case was deﬁned as a “core case” upon as-
signment of a positive Silhouette value. Subclass mapping was per-
formed to determine the common LMS subtypes based on these “core
cases” identiﬁed in the 3SEQ and TCGA RNASeq datasets.
In order to discover subtype-speciﬁc genes, SAMSeq [11] was per-
formed on both datasets (3SEQ and TCGA RNASeq) between each sub-
type and all other subtypes with a FDR of 0.05, and signiﬁcantly
differentially expressed genes from the SAMSeq analysis was referred
to identify the diagnostic biomarker for each LMS subtype.
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